Consider "UPEXI" as a way to gain exposure to the Solana blockchain at a nearly 30% discount to its asset value, presenting a significant buying opportunity after its recent price drop. Nebius is an undervalued AI infrastructure play whose new Microsoft partnership is expected to drive over 1600% revenue growth in the next year. For a higher-risk value trade, Oscar Health (OSCR) is considered "dirt cheap" with a potential political catalyst that could send the stock toward $30. As mortgage rates fall, The Real Brokerage (REAX) offers a cheap investment into a real estate market recovery, trading at a price-to-sales ratio of just 0.10. Finally, an investment in MicroStrategy (MSTR) is a leveraged bet on Bitcoin, which is believed to be near a bottom and poised for a rebound by year-end.

MicroStrategy (MSTR)

The speaker uses the code name "strategy" when referring to this company, a well-known holder of Bitcoin on its balance sheet. The analysis is highly correlated with the outlook for Bitcoin.

• Sentiment: Bullish.
• Valuation: The speaker notes that the stock's value relative to its Bitcoin holdings (the MNAV or Market to Net Asset Value) is compressing slowly, which is seen as a positive sign compared to other companies in the space.
• Market Activity: A recent spike in daily trading volume, surpassing even Microsoft, is interpreted as a potential sign of new traders entering the stock.
• Catalysts: The speaker believes the stock is closer to a bottom and is poised for a rebound due to several factors:
  • Bitcoin Correlation: Any positive news for Bitcoin is positive for MicroStrategy.
  • Macroeconomic Factors: Potential for rate cuts and an end to the government shutdown are seen as bullish. Positive developments in US-China trade relations could also boost risk assets like Bitcoin.
  • Capital Flows: As interest rates fall, trillions of dollars currently in money market accounts are expected to move into "risk-on" assets like Bitcoin, driving up its price.

Takeaways

• An investment in MSTR is presented as a leveraged bet on the price of Bitcoin.
• The speaker believes the stock is currently undervalued relative to its Bitcoin holdings and that multiple near-term economic and market catalysts could drive the price of both Bitcoin and MSTR higher by the end of the year.

Solana (SOL) & "UPEXI"

The speaker discusses Solana as a leading smart contract platform and highlights a specific, unnamed investment vehicle referred to as "UPEXI" as a way to gain discounted exposure.

• Sentiment: Bullish.
• Investment Thesis (Solana): The speaker believes blockchains like Solana will be the foundation of Web3, eventually replacing many traditional Web 2.0 companies (e.g., YouTube, banks, video games). Solana is highlighted as the fastest and cheapest blockchain currently available.
• Investment Thesis (UPEXI): UPEXI is presented as a company that holds a large amount of Solana, allowing investors to buy the stock and get exposure to SOL at a significant discount.
  • Valuation: The speaker calculates a basic MNAV (Market to Net Asset Value) of 0.72, meaning the company's market cap is only 72% of the value of the Solana it holds. This represents a nearly 30% discount.
  • Staking Rewards: The company actively stakes its Solana holdings, earning an estimated 10% annual yield. Based on this, the speaker calculates a "price to staking rewards" ratio (similar to a P/E ratio) of 7.2, calling it "super cheap."
  • Recent Performance: UPEXI has recently fallen 38% while Solana itself is only down about 13%, making the discount even more pronounced and "ridiculous."

Takeaways

• Solana is viewed as a high-growth, long-term investment in the future of Web3 applications.
• UPEXI is presented as a significantly undervalued, "super cheap" way to invest in Solana. The combination of the deep discount to its asset value and the income generated from staking rewards makes it a compelling opportunity, according to the speaker.
• The significant recent drop in UPEXI's price, far exceeding the drop in SOL, is seen as a major buying opportunity.

Tesla (TSLA)

Despite widespread media coverage, the speaker presents a very bullish, long-term case for Tesla, arguing that the market and media are focused on the wrong metrics.

• Sentiment: Very Bullish. The speaker notes it is their largest personal holding.
• Financials: The speaker dismisses the reported earnings (EPS) miss, stating it was due to a non-cash accounting decision related to the Dojo supercomputer. The focus should be on the fundamentals, which were record-breaking:
  • Highest-ever quarterly revenue.
  • Highest-ever cash flow.
  • Most cash ever on the balance sheet.
• Future Catalysts: The speaker believes the true value of Tesla lies in its long-term, visionary projects that analysts are currently overlooking.
  • Robotaxi: Expected to roll out to 10 cities by year-end.
  • CyberCab: Production anticipated for the second half of 2026.
  • Optimus Robot: Version 3 is described as a potential "iPhone moment" for Tesla, with plans to manufacture millions of units.
  • Full Self-Driving (FSD): Development of Hardware 5, said to be 40 times more powerful than Hardware 4, is a key long-term value driver.
• Market Position:
  • Competitors like Ford and GM are seen as struggling in the EV space, which is a long-term positive for Tesla.
  • Falling interest rates will make Tesla's vehicles more affordable for consumers, potentially boosting sales.

Takeaways

• The investment case for TSLA is not about short-term earnings but about its long-term vision and dominance in multiple future-facing industries (AI, robotics, energy, autonomous driving).
• The speaker sees the market's negative reaction to the recent earnings report as a misunderstanding, creating an opportunity for long-term investors who focus on cash flow and future growth catalysts.

Oscar Health (OSCR)

The speaker's interest in Oscar Health is purely based on its extremely low valuation, viewing it as a short-term, opportunistic play.

• Sentiment: Bullish, but with significant caveats.
• Valuation: The primary reason for owning the stock is that it is "dirt cheap."
  • The speaker cites an enterprise value to forward revenue of 0.14 and an enterprise value to forward gross profit of 0.78, calling the stock "crazy, crazy cheap."
• Business Fundamentals:
  • Recent sharp increases in insurance premiums are expected to lead to large revenue growth next year.
  • The speaker dislikes the health insurance business model due to heavy regulation and difficulty in making money.
• Wild Card Catalyst: A potential expansion of Affordable Care Act (ACA) subsidies after the government shutdown ends could make Oscar's plans much more attractive and is a major potential catalyst. The speaker notes speculation that this could send the stock back to $30.
• Risk/Strategy: This is explicitly described as a short-to-medium-term hold. The speaker would sell the position if the stock rallies and is no longer considered "cheap."

Takeaways

• OSCR is presented as a high-risk, high-reward "value play."
• The investment is a bet that the stock's extremely low valuation, combined with upcoming revenue growth and a potential political catalyst (ACA subsidy expansion), will lead to a significant price increase.
• This is not a long-term investment for the speaker, who plans to exit if the valuation becomes less compelling.

Nebius

The speaker discusses Nebius, a spin-off from the Russian tech giant Yandex, as a key player in the high-demand AI cloud computing space.

• Sentiment: Bullish.
• Investment Thesis: Nebius is positioned to capitalize on the massive demand for AI and GPU data centers. Its key advantages are:
  • Talent: The team consists of "big tech grade" engineers and management from Yandex.
  • Superior Offering: Unlike competitors who just rent "bare metal" servers, Nebius offers a full software stack and uses its relationships to integrate seamlessly with major clients.
  • Microsoft Partnership: A recent contract with Microsoft is seen as a "game changer" that validates the company's technology and business model.
• Growth & Valuation:
  • The speaker calculates that the Microsoft deal could lead to 1600% revenue growth over the next 12 months.
  • Despite a recent bounce, the stock is still considered "dirt cheap," trading at a price-to-sales ratio of 0.12.

Takeaways

• Nebius is presented as an undervalued "picks and shovels" play on the AI boom.
• The company's elite team and game-changing partnership with Microsoft are expected to drive explosive revenue growth, which the speaker believes is not yet reflected in the stock price.

Hims & Hers Health (HIMS)

The speaker views HIMS as a long-term winner that is fundamentally disrupting the healthcare industry, and advises investors to ignore short-term price swings.

• Sentiment: Very Bullish, long-term hold.
• Investment Thesis: The story is much bigger than people think, focused on the disruption of traditional healthcare, insurance, and doctor visits through its telehealth platform.
  • AI Integration: The company is well-positioned to be a first-mover in implementing AI for medical prescriptions.
  • Growth Avenues: New product lines like Testosterone and Menopause treatments are expected to be huge growth drivers, with Menopause potentially taking the HERS platform past a $1 billion revenue run rate.
• Valuation & Strategy:
  • The speaker has owned the stock since $5 and views recent volatility as "funny."
  • A recent dip has made the stock cheaper, trading at a price-to-sales ratio of 0.15.
  • Investors are encouraged to be long-term holders and not get shaken out by drawdowns.

Takeaways

• HIMS is a long-term growth investment based on the thesis that it is a major disruptor in the massive healthcare market.
• The speaker advises ignoring short-term volatility and focusing on the company's expanding product lines and strategic position as a next-generation healthcare platform. Recent dips are viewed as buying opportunities.

The Real Brokerage Inc. (REAX)

The speaker uses the code name "REACs" for this company, presenting it as an undervalued macro bet on a recovery in the real estate market. This is likely The Real Brokerage Inc. (REAX) based on the context.

• Sentiment: Bullish.
• Investment Thesis: This is a bet on the real estate market picking back up, driven by falling interest rates.
  • Macro Catalyst: The speaker highlights that the 10-year Treasury yield hit a 52-week low and U.S. mortgage rates fell to 6.19%, the lowest in over a year. They expect rates to fall below 5% by 2026.
  • Company Performance: The company has been growing revenue and gaining agents very quickly, even in a difficult housing market. The speaker implies its performance will accelerate significantly in a better environment.
• Valuation: The stock is described as "dirt cheap," trading at a price-to-sales ratio of 0.10.
• Timeline: The speaker believes the stock could rally into the end of the year or into the spring 2026 buying season as the real estate market improves.

Takeaways

• REAX is presented as a cheap, high-growth way to invest in a potential real estate market recovery.
• The investment is supported by both a strong macro trend (falling mortgage rates) and strong company-specific execution (gaining market share). The low valuation provides a potential margin of safety.